Literature DB >> 21896708

Varenicline: quantifying the risk.

Brian S Alper.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896708      PMCID: PMC3168637          DOI: 10.1503/cmaj.111-2071

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

Review 1.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

Review 2.  Nicotine receptor partial agonists for smoking cessation.

Authors:  Kate Cahill; Lindsay F Stead; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

3.  Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.

Authors:  Nancy A Rigotti; Andrew L Pipe; Neal L Benowitz; Carmen Arteaga; Dahlia Garza; Serena Tonstad
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

4.  Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

Authors:  D Gunnell; D Irvine; L Wise; C Davies; R M Martin
Journal:  BMJ       Date:  2009-10-01
  4 in total
  2 in total

1.  PURLs: Counseling is a must with this smoking cessation aid.

Authors:  Luke A Stephens; James J Stevermer
Journal:  J Fam Pract       Date:  2012-03       Impact factor: 0.493

2.  Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  BMJ       Date:  2012-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.